Boryung Pharm succeeded in avoidance of ‘Alimta Inj’ patent

Over the hydrate patent(Korea Patent Registration No. 0744917) related to the main substance of the recent lung cancer treatment ‘Alimta(generic name: pemetrexed disodium heptahydrate),’ Boryung Pharm(President Tae-hong Choi) has won the defensive confirmation trial for the scope of the right against the patentee, Eli Lilly, as receiving an affirmed decision.

Although the patent which protects...